GSK offers New Yorkers an ‘Alli Experience’

Share this article:
GlaxoSmithKline yesterday kicked off its educational campaign behind OTC diet pill Alli (orlistat), debuting a multimedia exhibit in New York’s bustling Union Square neighborhood. The free exhibit, dubbed the “Alli Experience,” was crafted with help from HealthSTAR Public Relations and is part of GSK’s $150 million marketing push behind the weight loss drug slated to go on sale June 15. Steve Burton, VP of the weight control division at GSK’s healthcare unit, told reporters during a press conference prior to exhibit’s opening to the public that he hopes the Alli Experience will help start the conversation that losing weight is hard work. “We’re not the total answer,” Burton said. “The answer is individual commitment in partnership with Alli and all the support and education the Alli program offers.” The Alli Experience will remain open to the public through June 10. In March, MM&M reported that GSK would also be making a foray into the world of publishing as part of its Alli marketing efforts, with a companion book featuring recipe and lifestyle tips. The 140-page soft-cover volume – titled Are You Losing It? – is expected to go on sale in retail outlets including Kmart and Wal-Mart beginning in this month. The FDA approved Alli in February as an OTC weight-loss aid for overweight adults to be used in conjunction with a reduced calorie diet and exercise program. Orlistat was first granted FDA approval in 1999 as the branded prescription product Xenical, which is sold in the US by Roche. Xenical will continue to be available in its 120 mg capsule prescription form while Alli will be sold in a 60 mg. dose. Alli will cost about $1.20 - $1.80-a-day, comparable to a bag of potato chips and a Diet Coke, Burton said. GSK has previously estimated that 5 million to 6 million Americans would buy the drug over the counter.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...